NY-CLARITY-AI/BLACKROCK
14.1.2021 15:54:37 CET | Business Wire | Press release
BlackRock Inc. (NYSE: BLK) today announced a minority investment in Clarity AI, a sustainability analytics and data science platform, as the firm continues to invest in delivering sustainable investing analytics and software for clients. BlackRock will integrate Clarity AI’s capabilities with Aladdin®, BlackRock’s end-to-end operating system for investment professionals.
Clarity AI uses big data and machine learning to create actionable sustainability and impact insights and expand these to a uniquely broad universe of companies, countries and local governments. Its proprietary technology and data science capabilities across environmental and social impact analyze more than 30,000 companies, spanning almost 200 countries. Clarity AI also supports regulatory and client reporting to help investors meet new sustainability disclosure obligations.
“Investors are galvanized around sustainability as a critical consideration in managing immediate and future risks, and better data is foundational to this,” said Mary-Catherine Lader, Head of Aladdin Sustainability at BlackRock . “As BlackRock makes sustainability its standard for investing, we are committed to raising the standards for ESG data and technology. We’re investing in new analytics and software in Aladdin and are also integrating capabilities from strategic partners like Clarity AI so clients can understand their investments’ social and environmental impact and risks. Clarity AI’s capabilities use machine learning to help Aladdin clients analyze a broader universe of companies, address their disclosure obligations and build more sustainable portfolios.”
“BlackRock’s investment in Clarity AI and the integration of our capabilities and comprehensive ESG, sustainability and impact data into BlackRock’s Aladdin platform will be transformative, bringing Clarity AI data and analytics to more of the world’s largest and most significant investors,” said Rebeca Minguela, Founder and CEO of Clarity AI . “This strategic partnership with BlackRock reflects the growing demand for our innovative approach in helping investors assess the impact of companies on our society and planet.”
Demand for sustainable investing accelerated rapidly in 2020. Global investors in mutual funds and ETFs invested $326billion in sustainable assets in the 12 months to November 2020, a 97% increase over the same period in the prior year1 . In addition, a recent survey2 of global investors shows that their allocations to ESG strategies are expected to double by 2025. Within the survey2, 53% of respondents cited concerns about “poor quality or availability of ESG data and analytics” as their biggest barrier to adopting sustainable investing. As more investors look for ways to evaluate the social and environmental impact of their investments, the need for improved ESG data and analytics in individual investments and across whole portfolios will continue to grow.
Clarity AI builds on the existing sustainability dataset in the Aladdin platform with additional forward-looking sustainability analytics and models, generated from data about companies. These insights complement traditional corporate ESG disclosures.
This investment is the latest step from BlackRock’s Aladdin platform as it continues to invest in its sustainability capabilities, which last year added 1,200 sustainability metrics and established data partnerships to help investors understand ESG and physical climate risks and opportunities.
BlackRock also recently unveiled Aladdin Climate, which helps investors understand and act on climate risk. It is the first software application to offer investors measures of both the physical risk of climate change and the transition risk to a low-carbon economy on portfolios.
BlackRock will join existing investors including Deutsche Börse, Kibo Ventures, Mundi Ventures, Seaya Ventures and Founders Fund.
The terms of the transaction were not disclosed.
About BlackRock
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate
About Aladdin
Aladdin® is BlackRock’s end-to-end investment management and operations platform used by institutional investors including asset managers, pension funds, insurers and corporate treasurers. It combines sophisticated risk analytics with comprehensive portfolio management, trading and operations tools on a single, unified platform. Also customized for wealth managers, the Aladdin platform provides a common language across the investment lifecycle and enables a culture of risk transparency among users.
About Clarity AI
Clarity AI is a global data science and technology platform that uses machine learning and big data to deliver environmental and social data that empowers investors to measure the impact of their portfolios. Clarity AI’s platform analyzes more than 30,000 companies, 200,000 funds and 400 countries and local governments, delivering data, analytics and software applications for investment and corporate research and reporting. Founded in 2017, Clarity AI has offices in the US, UK and Spain and a client network with over $10 trillion assets under management. Clarity AI’s team is specialized in technology, sustainability and research, with collective experience from leading organizations, businesses and research institutions including NASA, the World Bank, Google, McKinsey & Company, Morgan Stanley, J.P. Morgan, Harvard, M.I.T and more. For additional information on Clarity AI, please visit www.clarity.ai
1
Simfund, Broadridge, GBI. Data as of Nov 2020. Closed-end funds, FoFs excluded; Money Market funds included.
2
BlackRock 2020 Global Sustainable Investing Survey, which includes responses from 425 clients in 27 countries representing an estimated $25 trillion in assets under management: https://www.blackrock.com/corporate/literature/publication/blackrock-sustainability-survey.pdf
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005665/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom